J Clin Oncol: A comparative analysis of gifitinib VS gofitinia-giniandaandaandaandaandaanda-cala-calcin chemotherapy in EGFR mutant lung cancer.

The standard first-line treatment for EGFR mutant advanced non-small cell lung cancer (NSCLC) is an oral tyrosine kinase inhibitor directed by epidermal growth factor receptor (EGFR).
the addition of permeitus and carpenem chemotherapy on the basis of oral tyrosine kinase inhibitors can improve efficacy.
this is a Phase III randomized trial that included advanced NSCLC patients who were planned to receive first-line palliative care, with a sensitive mutation of EGFR with a performance status of 0 to 2.
randomly assigned to 1:1 to gifitinib 250mg/day oral (Gef) or gifitini 250mg/day oral garpermiquec 500mg/m2 and capium curve area 5 intravenous injections, once every 3 weeks, for a total of 4 cycles, and then maintained perminicce (gifitiniplus chemotherapy (Gef-C)
the primary endpoint is progression-free survival (PFS);
results, 350 patients were randomly assigned to Gef (n s 176) and Gef-C (n s 174) between 2016 and 2018.
21% of patients with a performance status of 2,18% had brain metastasis.
median follow-up time is 17 months (range, 7 to 30 months). The radiological response rates in the
Group Ofgf-C and Gef group were 75% and 63% respectively (P -01).
The estimated median PFS of Gef-C is significantly longer than Gef (16 months ( 95% CI, 13.5 to 18.5 months) ;P v 8 months (95% CI, 7.0 to 9.0 months);
estimates that the median OS of Gef-C is significantly longer than Gef (not reached v 17 months (95% CI, 13.5 to 20.5 months ;P);
clinically related level 3 or higher toxicity (P-lt; .001) occurred in 51% and 25% of patients in the Gef-C and Gef groups, respectively.
, the results show that adding permeitus and kappelin chemotherapy to the basis of gifitinib can significantly extend PFS and OS in NSCLC patients, but increase toxicity.
.